CCRII Enrolls 300+ Chicago Patients In Covid-19 Phase 3 Trial Announced

As nationally accredited leaders in the fight against the Covid-19 pandemic, Chicago Clinical Research Institute has previously collaborated with AstraZeneca for a Covid-19 prophylaxis study, which radically altered the approach of the medical community in the US to the disease. They also worked with Sanofi for a Covid-19 vaccine study that helped to pave the way for the mass vaccination rollouts which have taken place internationally. Now, with their latest trial, they are proud to announce their partnership with Regeneron, a leading biotechnology and pharmaceutical company based in New York, that has been at the forefront of medical science since their inception in 1988.

More details can be found at

Although many people have placed the Covid-19 pandemic in society’s collective rearview mirror, the WHO and the global health community remain attuned to its complexities and its ongoing implications for public health. With well over 1 million deaths recorded from the virus in the United States alone, Chicago Clinical Research Institute believes it is imperative that American medical institutions remain vigilant and continue to learn from SARS-CoV-2; understanding that the adaptable SARS strain may continue to mutate and may precipitate further pandemics of a similar nature.

As such, the organization is proud to detail the parameters of their most recent Phase III clinical trial to fellow Contract Research Organizations (CROs), pharmaceutical companies and sponsors, and to contribute their findings to this critical pool of ongoing research.

Chicago Clinical Research Institute’s recent top enroller trial enlisted over 300 patients to test the monoclonal-antibody combination known as AZD7442. Based upon the prophylactic and therapeutic effects it had displayed in the treatment of SARS-CoV-2 in animal models, CCRI proceeded with single-dose intramuscular testing within their patient sample.

The preliminary conclusions of the trial indicate that a single dose of AZD7442 is effective in the prevention of Covid-19, for a median period of at least six months, with potential for a quick regulatory start-up and without side effects.

CCRI’s full research paper, titled ‘Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19’, has now been published in The New England Journal of Medicine and can be accessed by interested readers at

Though mass vaccination efforts have heralded some success in the global fight against Covid-19, there remain many hindrances to full inoculation, including ideological ones. As such, Chicago Clinical Research Institute advocates for greater research into the use of monoclonal antibodies like AZD7442 as both preexposure and post-exposure prophylaxis.

Chicago Clinical Research Institute, Inc. was founded in 2005. They are a multi-disciplinary research facility that conducts phase ‘I’ to phase IV clinical trials independently and alongside the largest pharmaceutical developers and providers in the United States. Beyond their ground-breaking work in the fight against Covid-19, they have researched innovative treatments for debilitating conditions like Type II Diabetes and Alzheimer’s disease.

A spokesperson for the medical researchers said, “The data that resulted from our most recent trial provides support for the use of AZD7442 as immunoprophylaxis to prevent Covid-19. The primary efficacy analysis and the key supportive analyses met the statistical criterion for trial success. The incidences of symptomatic RT-PCR-positive SARS-CoV-2 infection and severe disease among infected participants were lower in the AZD7442 group than in the placebo group, and there were no evident safety concerns.??”

More information is available at

Chicago Clinical Research Institute, Inc. (CCRII)
611 West Roosevelt Road

United States

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Florida Times Daily journalist was involved in the writing and production of this article.